Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

bioMérieux to Move Immunoassay Production to New Shanghai JV

publication date: Jan 31, 2008

The French diagnostic test company bioMérieux (Euronext: BIM) will establish a joint venture in Shanghai with Shanghai Kehua Bio-engineering. The JV will assume production of bioMérieux’s diagnostic test kits. bioMérieux announced in late 2007 that it would gradually shutter its Boxtel plant in the Netherlands, where the kits are currently produced. Production of its microplate immunoassay line will moved to the new Shanghai JV, which will be 60% owned by bioMérieux. The immunoassays will be distributed world-wide. More details...

Stock Symbols: (Euronext: BIM) (SHE: 002022)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital